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 A new level of studies is needed to answer important questions about the expanding 
global chronic disease burden for cardiovascular disease (CVD) and related conditions such as 
diabetes, metabolic syndrome, and obesity. Interpretability of much existing research is limited 
by partial models, partial measures, and by partial populations. A new study design structure 
requires grounding in a new theory beyond the current single-factor, a-theoretic epidemiological 
studies. Such a new platform for the design of large-scale Work/Stress/Disease studies would 
assess CVD-related disease mechanisms in a more general and dynamic form.  It would be based 
on a new theory of disease causation, Stress-Disequilibrium Theory (SDT), and new Heart Rate 
Variability (HRV) data analytic strategies for measuring autonomic function exhaustion in an 
occupational stress context. The goal would be to assess the associations between social 
organizational risks, particularly at work, and hypertension, metabolic syndrome, and diabetes II. 
 SDT generates a new study design with (a) dual physiological pathways to address co-
morbidity: one through autonomic control of cardiac output, and another through autonomic 
control of glucose regulation. The study design also (b) requires a four-stages of 
Controller/Controlled relationships, spanning across several levels of disease-related de-
regulation: (1) from social risks at work, (2) through two disease development stages, and (3) 
looping back to social and distributional consequences of disease on working place organization.  
 A full-occupation-spectrum healthy working population is needed, large enough to assess 
disease development outcomes with statistical power - probably multi-site with several countries, 
and would include nested bio-monitoring and reliability studies. 
 
 
